Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer

Lu Huang, Zhi Liao, Zhixi Liu, Yan Chen, Tingwenli Huang, Hongtao XiaoFrontiers in Pharmacology 2022 · DOI

This review paper, published in Frontiers in Pharmacology, provides a comprehensive overview of how CRISPR/Cas9 technology is being leveraged to understand and overcome the "Achilles' heel" of lung cancer treatment: acquired drug resistance.

TL;DR

CRISPR/Cas9 is evolving from a laboratory tool into a potential therapeutic strategy to "reset" drug sensitivity in non-small cell lung cancer (NSCLC). By precisely knocking out resistance-driving mutations or screening for new vulnerabilities, researchers are finding ways to reverse multidrug resistance and improve the efficacy of targeted therapies like TKIs.

What Problem Does This Paper Address?

Non-small cell lung cancer (NSCLC) accounts for over 85% of lung cancer cases. While the advent of targeted therapies—specifically Tyrosine Kinase Inhibitors (TKIs) targeting mutations in genes like EGFR—initially showed great promise, patients almost inevitably develop resistance.

Tumors are highly adaptable; they develop secondary mutations (like the EGFR T790M or C797S variants), activate "bypass" signaling pathways, or ramp up "efflux pumps" that literally spit chemotherapy drugs out of the cell. This paper explores how CRISPR/Cas9 can be used to systematically identify these resistance mechanisms and potentially serve as a "molecular scalpel" to remove or correct the genetic instructions that allow cancer to survive treatment.

Methods

As a review article, the paper synthesizes current research on several CRISPR-based approaches:

  • Standard CRISPR/Cas9: Used to create double-strand breaks (DSBs) to knock out oncogenes or resistance-driving genes via Non-Homologous End Joining (NHEJ).
  • Homology-Directed Repair (HDR): A more precise method used to "swap" a mutated, drug-resistant gene sequence for a healthy, drug-sensitive wild-type sequence.
  • dCas9 (Dead Cas9): Utilizing a catalytically inactive Cas9 fused to transcriptional activators or repressors (CRISPRa/i). This allows researchers to turn gene expression up or down without permanently cutting the DNA.
  • High-Throughput Screening: Using CRISPR libraries to knock out thousands of genes across a cell population to see which specific deletions make a resistant tumor sensitive to drugs again.

Datasets

The paper does not introduce a new dataset; instead, it reviews findings from numerous primary studies and clinical trials, including:

  • Clinical Trials: Mentions the landmark 2020 trial by Lu et al., which was the first human clinical trial using CRISPR-edited T cells (knocking out the PD-1 gene) to treat metastatic NSCLC.
  • In Vivo Studies: Summarizes results from various mouse models where CRISPR was used to target KRAS, ALK, and EGFR mutations.

Key Insights and Ideas

  • CRISPR vs. RNAi: The authors argue that CRISPR is superior to traditional RNA interference (RNAi) for genetic screening. While RNAi only "knocks down" gene expression (leaving some protein behind), CRISPR provides a clean "knockout," leading to more reliable data with fewer off-target effects.
  • Molecular Surgery: The paper highlights the prospect of "individualized molecular surgical treatment," where CRISPR could be used in vivo to replace mutated exons in a patient's tumor, effectively reverting the cancer to a treatable state.
  • Targeting the "Pumps": A major insight is the use of CRISPR to disable ABC transporters (like P-gp). These proteins are often overexpressed in resistant tumors; knocking them out can significantly increase the intracellular concentration of chemotherapy drugs.
  • Epigenetic Resetting: Beyond just editing DNA sequences, the paper discusses using dCas9 to modify DNA methylation and histone acetylation, potentially "re-awakening" tumor suppressor genes that the cancer had silenced.

Key Results

  • KRAS Inhibition: In studies targeting the KRAS G12S mutation in A549 cell lines, CRISPR-mediated inhibition led to a 46% reduction in tumor volume in mouse models.
  • Reversing TKI Resistance: Research showed that knocking out EGFR in resistant cell lines significantly inhibited proliferation and induced cell cycle arrest in the G2/M phase.
  • Clinical Feasibility: The Lu et al. (2020) trial demonstrated that CRISPR-edited cells could be safely reinfused into patients, proving the technology's readiness for clinical exploration, even if efficacy is still being optimized.

Limitations and Future Work

Despite the excitement, the authors identify several "bottlenecks" that must be cleared before CRISPR becomes a standard bedside treatment:

  • Off-Target Effects: The risk of Cas9 cutting DNA at unintended sites remains a primary safety concern, as it could inadvertently create new mutations.
  • Delivery Efficiency: Getting the CRISPR machinery (Cas9 protein + guide RNA) into a high enough percentage of tumor cells in vivo is difficult. Current viral vectors (AAV, LV) have limited cargo capacity.
  • Immune Response: Many humans have pre-existing immunity to Cas9 proteins derived from common bacteria like S. pyogenes, which could lead to the body rejecting the treatment.
  • The p53 Paradox: CRISPR-induced DNA damage can trigger a p53-mediated stress response. This might inadvertently select for p53-deficient cells, which are often more aggressive and harder to treat.

The authors conclude that while CRISPR/Cas9 is not yet a "magic bullet," its ability to systematically deconstruct the logic of drug resistance makes it an indispensable tool for the next generation of precision oncology.

Summary updated

Abstract

Cancer drug resistance has always been a major factor affecting the treatment of non-small cell lung cancer, which reduces the quality of life of patients. The clustered regularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) technology, as an efficient and convenient new gene-editing technology, has provided a lot of help to the clinic and accelerated the research of cancer and drug resistance. In this review, we introduce the mechanisms of drug resistance in non-small cell lung cancer (NSCLC), discuss how the CRISPR/Cas9 system can reverse multidrug resistance in NSCLC, and focus on drug resistance gene mutations. To improve the prognosis of NSCLC patients and further improve patients' quality of life, it is necessary to utilize the CRISPR/Cas9 system in systematic research on cancer drug resistance.
BibTeX
@inproceedings{huang2022application,
  author = {Lu Huang and Zhi Liao and Zhixi Liu and Yan Chen and Tingwenli Huang and Hongtao Xiao},
  title = {{Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.900825},
}
Figure